The case for open science: rare diseases

JAMIA Open

Volumn 3, Issue 3, 2020, Pages 472-486

  Rubinstein, Yaffa R ^a   Robinson, Peter N ^b   Gahl, William A ^c   Avillach, Paul ^d   Baynam, Gareth ^e   Cederroth, Helene ^f   Goodwin, Rebecca M ^a   Groft, Stephen C ^g   Hansson, Mats G ^h   Harris, Nomi L ⁱ   Huser, Vojtech ^j   Mascalzoni, Deborah ^h   Mcmurry, Julie A ^k   Might, Matthew ^l   Nellaker, Christoffer ^m   Mons, Barend ⁿ   Paltoo, Dina N ^a   Pevsner, Jonathan ^o   Posada, Manuel ^p   Rockett Frase, Alison P ^q   Roos, Marco ⁿ   Rubinstein, Tamar B ^r   Taruscio, Domenica ^s   Van Enckevort, Esther ^t   Haendel, Melissa A ^k   more..

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b JACKSON LABORATORY   (United States)

^c NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f Wilhelm Foundation   (Sweden)

^g NATIONAL INSTITUTES OF HEALTH   (United States)

^h UPPSALA UNIVERSITY   (Sweden)

ⁱ LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^j NATIONAL INSTITUTES OF HEALTH   (United States)

^k OREGON STATE UNIVERSITY   (United States)

^l UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^m UNIVERSITY OF OXFORD   (United Kingdom)

ⁿ LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^o JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^p INSTITUTO DE SALUD CARLOS III   (Spain)

^q Joshua Frase Foundation   (United States)

^r ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^s ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^t UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

more..

Author keywords

common data elements; data standards; FAIR data; ontology; open science; rare disease patients

Indexed keywords

EID: 85107419339     PISSN: None     EISSN: 25742531     Source Type: Journal    
DOI: 10.1093/jamiaopen/ooaa030     Document Type: Review

References (172)

1. Taruscio D, Floridia G, Salvatore M, Groft SC, Gahl WA. Undiagnosed diseases: Italy-US collaboration and international efforts to tackle rare and common diseases lacking a diagnosis. Adv Exp Med Biol 2017; 1031: 25-38.
2. Richter T, Nestler-Parr S, Babela R, et al. Rare disease terminology and definitions-A systematic global review: report of the ISPOR Rare Disease Special Interest Group. Value Health 2015; 18 (6): 906-14.
3. Forrest CB, Bartek RJ, Rubinstein Y, Groft SC. The case for a global rare-diseases registry. Lancet 2011; 377 (9771): 1057-9.
4. Khosla N, Valdez R. A compilation of national plans, policies and government actions for rare diseases in 23 countries. Intractable Rare Dis Res 2018; 7 (4): 213-22.
5. Haendel M, Vasilevsky N, Unni D, et al. How many rare diseases are there? Nat Rev Drug Discov 2020; 19: 77-8.
6. Evans WR. Dare to think rare: diagnostic delay and rare diseases. Br J Gen Pract 2018; 68: 224-5.
7. Vandeborne L, van Overbeeke E, Dooms M, De Beleyr B, Huys I. Information needs of physicians regarding the diagnosis of rare diseases: a questionnaire-based study in Belgium. Orphanet J Rare Dis 2019; 14 (1): 99.
8. Colbaugh R, Glass K, Rudolf C, Tremblay Volv Global Lausanne Switzerland M. Learning to identify rare disease patients from electronic health records. AMIA Annu Symp Proc 2018; 2018: 340-7.
9. Haendel MA, Chute CG, Robinson PN. Classification, ontology, and precision medicine. N Engl J Med 2018; 379 (15): 1452-62.
10. Gahl WA, Markello TC, Toro C, et al. The National Institutes of Health Undiagnosed Diseases Program: insights into rare diseases. Genet Med 2012; 14 (1): 51-9.
11. Gahl WA, Boerkoel CF, Boehm M. The NIH Undiagnosed Diseases Program: bonding scientists and clinicians. Dis Model Mech 2012; 5 (1): 3-5.
12. Gahl WA, Tifft CJ. The NIH Undiagnosed Diseases Program: lessons learned. JAMA 2011; 305 (18): 1904-5.
13. Gall T, Valkanas E, Bello C, et al. Defining disease, diagnosis, and translational medicine within a homeostatic perturbation paradigm: the national institutes of health undiagnosed diseases program experience. Front Med (Lausanne) 2017; 4: 62.
14. Taruscio D, Groft SC, Cederroth H, et al. Undiagnosed Diseases Network International (UDNI): White paper for global actions to meet patient needs. Mol Genet Metab 2015; 116 (4): 223-5.
15. UDNI. UDNI. UDNI-Undiagnosed Diseases Network International. 2019. http://www.udninternational.org/ Accessed June 26, 2019.
16. Initiative on Rare and Undiagnosed Diseases (IRUD) j Japan Agency for Medical Research and Development. https://www.amed.go.jp/en/program/ IRUD/ Accessed December 24, 2019.
17. GO FAIR. Implementation Networks-GO FAIR. GO FAIR; 2019. https://www.go-fair.org/implementation-networks/ Accessed July 22, 2019.
18. Burgelman J-C, Pascu C, Szkuta K, et al. Open science, open data, and open scholarship: european policies to make science fit for the twentyfirst century. Front Big Data 2019; 2: 43.
19. Wilkinson MD, Dumontier M, Sansone S-A, et al. Evaluating FAIR maturity through a scalable, automated, community-governed framework. Sci Data 2019; 6 (1): 174.
20. Molster C, Youngs L, Hammond E, Dawkins H; National Rare Diseases Coordinating Committee, National Rare Diseases Working Group. Key outcomes from stakeholder workshops at a symposium to inform the development of an Australian national plan for rare diseases. Orphanet J Rare Dis 2012; 7 (1): 50.
21. Rare Diseases-GO FAIR. GO FAIR. https://www.go-fair.org/implementation-networks/overview/rare-diseases/ Accessed December 24, 2019.
22. Carbon S, Champieux R, McMurry JA, Winfree L, Wyatt LR, Haendel MA. An analysis and metric of reusable data licensing practices for biomedical resources. PLoS One 2019; 14 (3): e0213090.
23. Haendel. Socio-legal Barriers to Data Reuse. NLM Musings from the Mezzanine. 2019. https://nlmdirector.nlm.nih.gov/2019/06/11/socio-legal-barriers-to-data-reuse/ Accessed July 22, 2019.
24. Haendel M, Su A, McMurry J. FAIR-TLC: Metrics to Assess Value of Biomedical Digital Repositories: Response to RFI NOT-OD-16-133. 2016. https://zenodo.org/record/203295.
25. B2SHARE. https://b2share.eudat.eu/records/6ceeed13eb6340fcb132bcb 5b5e3d69a Accessed December 24, 2019.
26. Donoho D. 50 years of data science. J Comput Graph Stat 2017; 26 (4): 745-66.
27. Shefchek KA, Harris NL, Gargano M, et al. The Monarch Initiative in 2019: an integrative data and analytic platform connecting phenotypes to genotypes across species. Nucleic Acids Res 2020; 48 (D1): D704-15.
28. Biomedical Data Translator. National Center for Advancing Translational Sciences; 2017. https://ncats.nih.gov/translator Accessed December 24, 2019.
29. Biomedical Data Translator Consortium. Toward a universal biomedical data translator. Clin Transl Sci 2019; 12: 86-90.
30. Biomedical Data Translator Consortium. The Biomedical Data Translator Program: conception, culture, and community. Clin Transl Sci 2019; 12: 91-4.
31. Guo Y, Heath AP, Raman P, et al. Gabriella Miller Kids First Data Resource Center: Harmonizing genomic and clinical information to support childhood cancer and structural birth defect research. Eur J Hum Genet 2019; 27: 1174-813.
32. (Re)usable Data Project. http://www.reusabledata.org Accessed December 24, 2019.
33. OpenPHACTS. Open PHACTS. Open PHACTS. 2019. https://www. openphactsfoundation.org/ Accessed July 23, 2019.
34. CNMR. Centro Nazionale Malattie Rare. Centro Nazionale Malattie Rare; 2019. http://old.iss.it/cnmr/? lang=1&id=2662&tipo=3 Accessed June 26, 2019.
35. Vernon M, Marsh K. Patient engagement in clinical trial protocol design and recruitment strategies: what does it mean for orphan drug manufacturers? Evidera 2019: 1-4. https://www.evidera.com/patient-engagement-in-clinical-trial-protocol-design-and-recruitment-strategieswhat-does-it-mean-for-orphan-drug-manufacturers/.
36. Lapteva L, Vatsan R, Purohit-Sheth T. Regenerative medicine therapies for rare diseases. Transl Sci Rare Dis 2018; 3 (3-4): 121-32.
37. Schliebner S, Pruitt B. How Technology is Reshaping the Rare Disease Landscape. 2018. https://prahs.com/resources/whitepapers/Technology %20Reshaping%20Rare%20Disease-PRA%20White%20Paper.pdf Accessed December 15, 2019.
38. NCTS. About the RDCRN j The Rare Diseases Clinical Research Network. National Center for Advancing Translational Sciences; 2015. https://ncats.nih.gov/rdcrn/about Accessed July 23, 2019.
39. EURODIS. EURORDIS Rare Diseases Europe. EURORDIS; 2019. https://www.eurordis.org/ Accessed July 23, 2019.
40. PCORI. Rare Diseases Topic Spotlight. Patient Centered Outcomes Research Institute; 2018. https://www.pcori.org/research-results/topics/ rare-diseases Accessed July 23, 2019.
41. Genetic Alliance. Genetic Alliance. Genetic Alliance; 2019. http://www. geneticalliance.org/ Accessed July 23, 2019.
42. NORD. National Organization for Rare Disorders. National Organization for Rare Disorders; 2019. https://rarediseases.org/ Accessed July 23, 2019.
43. IMI Innovative Medicines Initiative j PARADIGM j Patients active in research and dialogues for an improved generation of medicines: advancing meaningful patient engagement in the life cycle of medicines for better health outcomes. IMI Innovative Medicines Initiative. https:// www.imi.europa.eu/projects-results/project-factsheets/paradigm Accessed May 20, 2020.
44. Swan USA. Swan USA. http://swanusa.org/ Accessed Decembe 24, 2019.
45. Genes G. Global Genes Partners with SWAN USA to Help Undiagnosed Rare Disease Patients Seek a Medical Diagnosis through Free Whole Exome Sequencing Program. PR Newswire; 2014. https://www.prnews wire.com/news-releases/global-genes-partners-with-swan-usa-to-helpundiagnosed-rare-disease-patients-seek-a-medical-diagnosis-throughfree-whole-exome-sequencing-program-243552661.html Accessed Decembe 24, 2019.
46. Home j SWAN UK. SWAN UK. https://www.undiagnosed.org.uk/ Accessed Decembe 24, 2019.
47. GeneDx, OPKO Health, Inc. OPKO's GeneDx Recognizes International Rare Disease Day with Donation of Free Exome Tests to Syndromes without a Name. PR Newswire; 2016. https://www.prnewswire.com/ news-releases/opkos-genedx-recognizes-international-rare-disease-day-withdonation-of-free-exome-tests-to-syndromes-without-a-name-300227519. html Accessed Decembe 24, 2019.
48. NGLY1.org-N-Glycanase Deficiency-NGLY1. NGLY1. http:// Ngly1.org Accessed Decembe 24, 2019.
49. Weintraub K. A Battle Plan for a War on Rare Diseases. The New York Times. 2018. https://www.nytimes.com/2018/09/10/health/matthewmight-rare-diseases.html Accessed Decembe 24, 2019.
50. Chordoma Foundation. Chordoma Foundation. Chordoma Foundation; 2019. https://www.chordomafoundation.org/ Accessed July 23, 2019.
51. CDCN. Castleman Disease Collaborative Network. Castleman Disease Collaborative Network; 2019. https://www.cdcn.org/ Accessed July 23, 2019.
52. Frase J. The Joshua Frase Foundation Supports Research for Myotubular Myopathy. The Joshua Frase Foundation Supports Research for MyotubularMyopathy; 2019. https://www.joshuafrase.org/ Accessed July 23, 2019.
53. CFF. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation; 2019. https://www.cff.org/ Accessed July 23, 2019.
54. PXE International j PXE International. https://www.pxe.org/ Accessed May 20, 2020.
55. NIH. NIH Releases Strategic Plan for Data Science. NIH News & Events; 2018. https://www.nih.gov/news-events/news-releases/nihreleases-strategic-plan-data-science Accessed July 17, 2019.
56. NLM. NLM Launches 2017-2027 Strategic Plan. NLM News & Events. U.S. National Library of Medicine; 2018. https://www.nlm.nih.gov/ news/NLM-Launches-2017-to-2027-Strategic-Plan.html Accessed July 17, 2019.
57. Shen F, Zhao Y, Wang L, et al. Rare disease knowledge enrichment through a data-driven approach. BMC Med Inform Decis Mak 2019; 19 (1): 32.
58. Arbabi A, Adams DR, Fidler S, Brudno M. Identifying clinical terms in medical text using ontology-guided machine learning. JMIR Med Inform 2019; 7 (2): e12596.
59. Sheehan J, Hirschfeld S, Foster E, et al. Improving the value of clinical research through the use of common data elements. Clin Trials 2016; 13 (6): 671-6.
60. NIH Common Data Elements (CDE) Repository. https://cde.nlm.nih. gov/ Accessed February 6, 2020.
61. NIH Common Data Element (CDE) Resource Portal. NIH Common Data Element (CDE) Resource Portal. U.S. National Library of Medicine; 2012. https://www.nlm.nih.gov/cde/index.html Accessed February 6, 2020.
62. Goetz KE, Reeves MJ, Tumminia SJ, Brooks BP. eyeGENE(R): a novel approach to combine clinical testing and researching genetic ocular disease. Curr Opin Ophthalmol 2012; 23 (5): 355-63.
63. Redeker NS, Anderson R, Bakken S, et al. Advancing symptom science through use of common data elements. J Nurs Scholarsh 2015; 47 (5): 379-88.
64. Moore SM, Schiffman R, Waldrop-Valverde D, et al. Recommendations of common data elements to advance the science of self-management of chronic conditions. J Nurs Scholarsh 2016; 48 (5): 437-47.
65. Corwin EJ, Moore SM, Plotsky A, et al. Feasibility of combining common data elements across studies to test a hypothesis. J Nurs Scholarsh 2017; 49 (3): 249-58.
66. Knisely MR, Maserati M, Heinsberg LW, et al. Symptom science: advocating for inclusion of functional genetic polymorphisms. Biol Res Nurs 2019; 21 (4): 349-54.
67. Corwin EJ, Berg JA, Armstrong TS, et al. Envisioning the future in symptom science. Nurs Outlook 2014; 62 (5): 346-51.
68. Page GG, Corwin EJ, Dorsey SG, et al. Biomarkers as common data elements for symptom and self-management science. J Nurs Scholarsh 2018; 50 (3): 276-86.
69. Menon DK, Schwab K, Wright DW, Maas AI. Demographics and clinical assessment working group of the international and interagency initiative toward common data elements for research on traumatic brain injury and psychological health. Position statement: definition of traumatic brain injury. Arch Phys Med Rehabil 2010; 91 (11): 1637-40.
70. Roos M, López Martin E, Wilkinson MD. Preparing data at the source to foster interoperability across rare disease resources. Adv Exp Med Biol 2017; 1031: 165-79.
71. Nelson LD, Ranson J, Ferguson AR, et al. Validating multidimensional outcome assessment using the TBI common data elements: an analysis of the TRACK-TBI pilot sample. J Neurotrauma 2017; 34 (22): 3158-72.
72. Duhaime A-C, Gean AD, Haacke EM, et al. Common data elements in radiologic imaging of traumatic brain injury. Arch Phys Med Rehabil 2010; 91 (11): 1661-6.
73. Cheadle C, Cao H, Kalinin A, Hodgkinson J. Advanced literature analysis in a big data world. Ann NYAcad Sci 2017; 1387 (1): 25-33.
74. Abhyankar S, Goodwin RM, Sontag M, Yusuf C, Ojodu J, McDonald CJ. An update on the use of health information technology in newborn screening. Semin Perinatol 2015; 39 (3): 188-93.
75. Abhyankar S, Lloyd-Puryear MA, Goodwin R, et al. Standardizing newborn screening results for health information exchange. AMIA Annu Symp Proc 2010; 2010: 1-5.
76. Hendershot T, Pan H, Haines J, et al. Using the PhenX toolkit to add standard measures to a study. Curr Protoc Hum Genet 2015; 86: 1.21.1-17.
77. Rubinstein YR, McInnes P. NIH/NCATS/GRDR® common data elements: a leading force for standardized data collection. Contemp Clin Trials 2015; 42: 78-80.
78. PhenX Toolkit. http://phenxtoolkit.org Accessed December 23, 2019.
79. PhenX Toolkit: Domains. http://phenxtoolkit.org/domains/view/220000 Accessed December 23, 2019.
80. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform 2019; 95: 103208.
81. Köhler S, Carmody L, Vasilevsky N, et al. Expansion of the human phenotype ontology (HPO) knowledge base and resources. Nucleic Acids Res 2019; 47 (D1): D1018-27.
82. Robinson PN, Kö hler S, Bauer S, Seelow D, Horn D, Mundlos S. The human phenotype ontology: a tool for annotating and analyzing human hereditary disease. Am J Hum Genet 2008; 83 (5): 610-5.
83. Mungall CJ, McMurry JA, Kö hler S, et al. The Monarch Initiative: an integrative data and analytic platform connecting phenotypes to genotypes across species. Nucleic Acids Res 2017; 45 (D1): D712-22.
84. Mungall CJ, Washington NL, Nguyen-Xuan J, et al. Use of model organism and disease databases to support matchmaking for human disease gene discovery. Hum Mutat 2015; 36 (10): 979-84.
85. McMurry JA, Kö hler S, Washington NL, et al. Navigating the phenotype Frontier: the Monarch initiative. Genetics 2016; 203 (4): 1491-5.
86. Köhler S, Schulz MH, Krawitz P, et al. Clinical diagnostics in human genetics with semantic similarity searches in ontologies. Am J Hum Genet 2009; 85 (4): 457-64.
87. Bauer S, Kö hler S, Schulz MH, Robinson PN. Bayesian ontology querying for accurate and noise-tolerant semantic searches. Bioinformatics 2012; 28 (19): 2502-8.
88. Schulz MH, Kö hler S, Bauer S, Vingron M, Robinson PN. Exact score distribution computation for ontological similarity searches. BMC Bioinformatics 2011; 12: 441.
89. Chief Medical Officer annual report 2016: Generation Genome. GOV.UK. https://www.gov.uk/government/publications/chief-medicalofficer-annual-report-2016-generation-genome Accessed June 30, 2018.
90. Bone WP, Washington NL, Buske OJ, et al. Computational evaluation of exome sequence data using human and model organism phenotypes improves diagnostic efficiency. Genet Med 2016; 18 (6): 608-17.
91. Groza T, Kö hler S, Moldenhauer D, et al. The human phenotype ontology: semantic unification of common and rare disease. Am J Hum Genet 2015; 97 (1): 111-24.
92. Vasilevsky NA, Foster ED, Engelstad ME, et al. Plain-language medical vocabulary for precision diagnosis. Nat Genet 2018; 50 (4): 474-6.
93. IRDiRC. IRDiRC Recognized Resources. IRDiRC; 2018. http://www. irdirc.org/research/irdirc-recognized-resources/current-irdirc-recognizedresources/ Accessed July 17, 2019.
94. Zhang XA, Yates A, Vasilevsky N, et al. Semantic integration of clinical laboratory tests from electronic health records for deep phenotyping and biomarker discovery. NPJ Digit Med 2019; 2: 32.
95. Konopka BM. Biomedical ontologies-a review. Biocybern Biomed Eng 2015; 35 (2): 75-86.
96. Amberger JS, Bocchini CA, Schiettecatte F, Scott AF, Hamosh A. OMIM. org: Online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic disorders. Nucleic Acids Res 2015; 43 (D1): D789-98.
97. Amberger JS, Bocchini CA, Scott AF, Hamosh A. OMIM.org: leveraging knowledge across phenotype-gene relationships. Nucleic Acids Res 2019; 47 (D1): D1038-43.
98. Vasant D, Chanas L, Malone J, et al. Orphanet Rare Disease ontology (ORDO): An Ontology Connecting Rare Disease, Epidemiology and Genetic Data. https://www.orpha.net/consor/cgi-bin/index.php.
99. RD-Connect. RD-Connect Sample Catalogue. RD-Connect Sample Catalogue; 2019. https://samples.rd-connect.eu/ Accessed July 17, 2019.
100. van Enkenvort D. Molgenis-Rdconnect-Report. Github; 2018. https://github. com/djvanenckevort/molgenis-rdconnect-report Accessed June 26, 2019.
101. Horaitis O, Talbot CC Jr, Phommarinh M, Phillips KM, Cotton R. A database of locus-specific databases. Nat Genet 2007; 39 (4): 425.
102. Fokkema I, Taschner PEM, Schaafsma GCP, Celli J, Laros JFJ, den Dunnen JT. LOVD v.2.0: the next generation in gene variant databases. Hum Mutat 2011; 32 (5): 557-63.
103. MacArthur J, Bowler E, Cerezo M, et al. The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog). Nucleic Acids Res 2017; 45 (D1): D896-D901.
104. NCBI Resource Coordinators. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 2016; 44: D7-19.
105. Landrum MJ, Lee JM, Benson M, et al. ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res 2016; 44 (D1): D862-8.
106. Buniello A, MacArthur JAL, Cerezo M, et al. The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res 2019; 47 (D1): D1005-12.
107. Wg OT. Mondo Disease Ontology. http://obofoundry.org/ontology/ mondo.html Accessed January 30, 2020.
108. Mungall CJ, Koehler S, Robinson P, Holmes I, Haendel M. k-BOOM: a Bayesian approach to ontology structure inference, with applications in disease ontology construction. bioRxiv 2019: 048843. https://www.biorxiv.org/content/10.1101/048843v3 Accessed December 14, 2019.
109. Wright CF, FitzPatrick DR, Firth HV. Paediatric genomics: diagnosing rare disease in children. Nat Rev Genet 2018; 19 (5): 325-325.
110. Philippakis AA, Azzariti DR, Beltran S, Brookes AJ, et al. The Matchmaker Exchange: a platform for rare disease gene discovery. Hum Mutat 2015; 36 (10): 915-21.
111. phenopacket-schema. Github. https://github.com/phenopackets/phenopacket-schema Accessed December 24, 2019.
112. Southall NT, Natarajan M, Lau LPL, et al.; on behalf of the IRDiRC Data Mining and Repurposing Task Force. The use or generation of biomedical data and existing medicines to discover and establish new treatments for patients with rare diseases-recommendations of the IRDiRC Data Mining and Repurposing Task Force. Orphanet J Rare Dis 2019; 14 (1): 225.
113. Robinson PN, Köhler S, Oellrich A, Wang K, Mungall CJ, et al.; Sanger Mouse Genetics Project. Improved exome prioritization of disease genes through cross-species phenotype comparison. Genome Res 2014; 24 (2): 340-8.
114. Exomiser. Github. https://github.com/exomiser/Exomiser Accessed December 23, 2019.
115. Taruscio D, Gainotti S, Mollo E, et al. The current situation and needs of rare disease registries in Europe. Public Health Genomics 2013; 16 (6): 288-98.
116. European Medicines Agency. European Medicines Agency; 2020. https:// www.ema.europa.eu/en?cookies=disabled Accessed May 20, 2020.
117. Alonso-Ferreira V, Sánchez-Díaz G, Villaverde-Hueso A, Posada de la Paz M, Bermejo-Sánchez E. A Nationwide Registry-based study on mortality due to rare congenital anomalies. Int J Environ Res Public Health 2018; 15 (8): 1715.
118. Mazzucato M, Visonà Dalla Pozza L, Minichiello C, et al. The epidemiology of transition into adulthood of rare diseases patients: results from a population-based registry. Int J Environ Res Public Health 2018; 15 (10): 2212.
119. Jansen-van der Weide MC, Gaasterland CMW, Roes KCB, et al. Rare disease registries: potential applications towards impact on development of new drug treatments. Orphanet J Rare Dis 2018; 13 (1): 154.
120. Taruscio D, Mollo E, Gainotti S, Posada de la Paz M, Bianchi F, Vittozzi L. The EPIRARE proposal of a set of indicators and common data elements for the European platform for rare disease registration. Arch Public Health 2014; 72 (1): 35.
121. Weldring T, Smith S. Patient-reported outcomes (PROs) and patientreported outcomemeasures (PROMs). Health Serv Insights 2013; 6: 61-8.
122. Maaroufi M, Landais P, Messiaen C, Jaulent M-C, Choquet R. Federating patients identities: the case of rare diseases. Orphanet J Rare Dis 2018; 13 (1): 199.
123. Coi A, Santoro M, Villaverde-Hueso A, et al. The quality of rare disease registries: evaluation and characterization. Public Health Genomics 2016; 19 (2): 108-15.
124. Ambinder EP. Electronic health records. JOP 2005; 1 (2): 57-63.
125. Timotijevic L, Barnett J, Brown K, Raats MM, Shepherd R. Scientific decision-making and stakeholder consultations: the case of salt recommendations. Soc Sci Med 2013; 85: 79-86.
126. Registry & Biobank Finder for Registries-RD-Connect. https://rdconnect. eu/what-we-do/phenotypic-data/rb-finder-for-registries/ Accessed December 24, 2019.
127. Santanello N, Largent J, Myers E, Smalley JB. Engaging Patients as Partners throughout the Registry Life Cycle. Rockville, MD: Agency for Healthcare Research and Quality (US); 2018.
128. Brasil S, Pascoal C, Francisco R, Dos Reis Ferreira V, Videira PA, Valadão AG. Artificial intelligence (AI) in rare diseases: is the future brighter? Genes 2019; 10 (12): 978.
129. Hsieh T-C, Mensah MA, Pantel JT, et al. PEDIA: prioritization of exome data by image analysis. Genet Med 2019; 21 (12): 2807-14.
130. Gurovich Y, Hanani Y, Bar O, et al. Identifying facial phenotypes of genetic disorders using deep learning. Nat Med 2019; 25 (1): 60-4.
131. Kline AD, Moss JF, Selicorni A, et al. Diagnosis and management of Cornelia de Lange syndrome: first international consensus statement. Nat Rev Genet 2018; 19 (10): 649-66.
132. Hammond P, Suttie M, Hennekam RC, Allanson J, Shore EM, Kaplan FS. The face signature of fibrodysplasia ossificans progressiva. Am J Med Genet A 2012; 158A (6): 1368-80.
133. Kung S, Walters M, Claes P, Goldblatt J, Le Souef P, Baynam G. A dysmorphometric analysis to investigate facial phenotypic signatures as a foundation for non-invasive monitoring of lysosomal storage disorders. JIMD Rep 2013; 8: 31-9.
134. Hu H, Haas SA, Chelly J, et al. X-exome sequencing of 405 unresolved families identifies seven novel intellectual disability genes. Mol Psychiatry 2016; 21 (1): 133-48.
135. Baynam GS, Walters M, Dawkins H, Bellgard M, Halbert AR, Claes P. Objective monitoring of mTOR inhibitor therapy by three-dimensional facial analysis. Twin Res Hum Genet 2013; 16 (4): 840-4.
136. Kung S, Walters M, Claes P, et al. Monitoring of therapy for mucopolysaccharidosis type I using dysmorphometric facial phenotypic signatures. JIMD Rep 2015; 22: 99-106.
137. Cliniface. Cliniface. Cliniface; 2019. https://cliniface.org/ Accessed July 23, 2019.
138. Face2Gene. Face2Gene. Face2Gene; 2019. https://www.face2gene.com/ Accessed July 23, 2019.
139. FaceBase. FaceBase. FaceBase; 2019. https://www.facebase.org/ Accessed July 23, 2019.
140. Ramesh AN, Kambhampati C, Monson JRT, Drew PJ. Artificial intelligence in medicine. Ann R Coll Surg Engl 2004; 86 (5): 334-8.
141. Feng S, Liu S, Zhu C, Gong M, Zhu Y, Zhang S. National rare diseases registry system of china and related cohort studies: vision and roadmap. Hum Gene Ther 2018; 29 (2): 128-35.
142. Patient Archive. Patient Archive. Patient Archive; 2019. http://patientarchive. org/#/home Accessed July 23, 2019.
143. Nellåker C, Alkuraya F, Baynam G, et al.; Minerva Consortium. Enabling global clinical collaborations on identifiable patient data: the Minerva Initiative. Front Genet 2019; 10: 611.
144. Austin CP, Cutillo CM, Lau LPL, et al.; on behalf of the International Rare Diseases Research Consortium (IRDiRC). Future of rare diseases research 2017-2027: an IRDiRC perspective. Clin Transl Sci 2018; 11 (1): 21-7.
145. Minerva & Me. Minerva and Me-Help Rare Disease Research. Minerva and Me; 2019. https://www.minervaandme.com/ Accessed July 23, 2019
146. Claes P, Liberton DK, Daniels K, et al. Modeling 3D facial shape from DNA. PLoS Genet 2014; 10 (3): e1004224.
147. Gahl WA. The battlefield of rare diseases: where uncommon insights are common. Sci Transl Med 2012; 4 (154): 154ed7.
148. Strode SW, Gustke S, Allen A. Technical and clinical progress in telemedicine. JAMA 1999; 281 (12): 1066-8.
149. HIMSS. HIMSS Analytics. HIMSS Analytics; 2019. https://www.himssanalytics. org/ Accessed July 17, 2019
150. Edworthy SM. Telemedicine in developing countries. BMJ 2001; 323 (7312): 524-5.
151. Augustine EF, Dorsey ER, Saltonstall PL. The care continuum: an evolving model for care and research in rare diseases. Pediatrics 2017; 140 (3): e20170108.
152. Darkins A, Sanders JH. Remote patient monitoring in home healthcare: lessons learned from advanced users. J Manage Market Healthcare 2009; 2 (3): 238-52.
153. Hinsch N, Rauofi R, Stauch G. Benign cystic mesothelioma of the peritoneum in a 12-year-old boy, diagnosed via telepathology. BMJ Case Rep 2015; 2015: bcr2015211419.
154. Siegert CJ, Fisichella PM, Moseley JM, Shoni M, Lebenthal A. Open access phone triage for veterans with suspected malignant pleural mesothelioma. J Surg Res 2017; 207: 108-14.
155. Tagliente I, Trieste L, Solvoll T, Murgia F, Bella S. Telemonitoring in cystic fibrosis: a 4-year assessment and simulation for the next 6 years. Interact J Med Res 2016; 5 (2): e11.
156. Sun C, Sun L, Xi S, et al. Mobile phone-based telemedicine practice in older Chinese patients with type 2 diabetes mellitus: randomized controlled trial. JMIR Mhealth Uhealth 2019; 7 (1): e10664.
157. Sasso FC, Pafundi PC, Gelso A, et al.; on behalf of NO BLIND Study Group. Telemedicine for screening diabetic retinopathy: the NO BLIND Italian multicenter study. Diabetes Metab Res Rev 2018; 35: e3113.
158. Vujosevic S, Pucci P, Casciano M, et al. A decade-long telemedicine screening program for diabetic retinopathy in the north-east of Italy. J Diabetes Complications 2017; 31 (8): 1348-53.
159. Ting DSW, Tan G. Telemedicine for diabetic retinopathy screening. JAMA Ophthalmol 2017; 135 (7): 722-3.
160. Duis J, van Wattum PJ, Scheimann A, et al. A multidisciplinary approach to the clinical management of Prader-Willi syndrome. Mol Genet Genomic Med 2019; 7 (3): e514.
161. Strickler AS, Palma J, Charris R, et al. Contribution of the use of basic telemedicine tools to the care of children and adolescents with juvenile idiopathic arthritis at the Puerto Montt Hospital, Chile. Rev Chil Pediatr 2018; 89 (1): 59-66.
162. Bashshur RL, Shannon GW, Smith BR, et al. The empirical foundations of telemedicine interventions for chronic disease management. Telemed J E Health 2014; 20 (9): 769-800.
163. Baker DB, Kaye J, Terry SF. Governance through privacy, fairness, and respect for individuals. eGEMs 2016; 4 (2): 7.
164. Fecher B, Friesike S. Open Science: one term, five schools of thought. In: Bartling S, Friesike S, eds. Opening Science: The Evolving Guide on How the Internet is Changing Research, Collaboration and Scholarly Publishing. Cham: Springer International Publishing; 2014: 17-47.
165. Leonelli S. Locating ethics in data science: responsibility and accountability in global and distributed knowledge production systems. Philos Trans A Math Phys Eng Sci 2016; 374: 20160122.
166. Science International. Open Data in a Big Data World. 2015. https:// council.science/publications/open-data-in-a-big-data-world Accessed December 10, 2019.
167. European Union. Open innovation, open science, open to the world: a vision for Europe. Moedas C, ed. Luxembourg: Publications Office of the European Union; 2015.
168. National Academies of Sciences, Engineering, and Medicine, Policy and Global Affairs, Board on Research Data and Information, Committee on Toward an Open Science Enterprise. In: Open Science by Design: Realizing a Vision for 21st Century Research. Washington, DC: National Academies Press; 2018.
169. EU. A Code of Conduct for Health Research. EU General Data Protection Regulation; 2018. http://code-of-conduct-for-health-research.eu/.
170. National Institutes of Health. Final NIH Genomic Data Sharing Policy. Federal Register; 2014: 51345-54. https://www.federalregister.gov/d/ 2014-20385.
171. Kass N. On the Ethics of Open Science. Sage Bionetworks; 2019. https:// sagebionetworks.org/in-the-news/on-the-ethics-of-open-science-2/ Accessed July 23, 2019.
172. International Indigenous Data Sovereignty IG. RDA; 2017. https://www. rd-alliance.org/groups/international-indigenous-data-sovereignty-ig Accessed December 30, 2019.